NCT03593187View on ClinicalTrials.gov

A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

July 28, 2020

Study Completion Date

July 28, 2020

Conditions
HIV-1 Infection
Interventions
DRUG

Cal-1 (LVsh5/C46) drug product

Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct

Trial Locations (1)

75475

Hôpital Saint Louis, Paris

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03593187 - A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma | Biotech Hunter | Biotech Hunter